A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease

Nonparametric Estimation from Incomplete Observations

1992 • 45,923 citations

Nonparametric Estimation from Incomplete Observations

1958 • 37,219 citations

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

2000 • 15,583 citations

Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung Cancer

2002 • 1,346 citations

Gastrosplenic Fistula From Hodgkin's Lymphoma

2009 • 735 citations

Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).

2001 • 716 citations

Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer

2006 • 654 citations

Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124

2009 • 507 citations

Small Cell Lung Cancer

2008 • 450 citations

Comprehensive Analysis ofUGT1APolymorphisms Predictive for Pharmacokinetics and Treatment Outcome in Patients With Non–Small-Cell Lung Cancer Treated With Irinotecan and Cisplatin

2006 • 295 citations

Irinotecan Plus Carboplatin Versus Oral Etoposide Plus Carboplatin in Extensive Small-Cell Lung Cancer: A Randomized Phase III Trial

2008 • 168 citations

Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells.

1996 • 160 citations

Open-Label, Multicenter, Randomized, Phase III Study Comparing Oral Topotecan/Cisplatin Versus Etoposide/Cisplatin As Treatment for Chemotherapy-Naive Patients With Extensive-Disease Small-Cell Lung Cancer

2006 • 140 citations

A useful testing strategy in phase iii trials: combined test of superiority and test of equivalence

1995 • 140 citations

Third-Generation Chemotherapy Agents in the Treatment of Advanced Non-small Cell Lung Cancer: A Meta-Analysis

2007 • 120 citations

A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer

2006 • 78 citations

Irinotecan (CPT-11): pharmacology and clinical applications

1996 • 60 citations

Interpreting Disparate Responses to Cancer Therapy: The Role of Human Population Genetics

2006 • 52 citations

2006 Highlights From: 42nd Annual Meeting of the American Society of Clinical Oncology Atlanta, GA, June 2006

2006 • 37 citations

Topotecan/cisplatin (TP) compared to cisplatin/etoposide (PE) for patients with extensive disease-small cell lung cancer (ED- SCLC): Final results of a randomised phase III trial

2008 • 29 citations

Progress in treatment of small-cell lung cancer: role of CPT-11

2003 • 19 citations

Cisplatin (Cis)/etoposide (VP16) compared to cis/irinotecan (CPT11) in extensive-stage small cell lung cancer (E-SCLC): Pharmacogenomic (PG) and comparative toxicity analysis of JCOG 9511 and SWOG 0124

2007 • 19 citations

Three-week schedule of irinotecan and cisplatin in advanced non-small cell lung cancer: a multicentre phase II study

2003 • 18 citations

Third-Generation Chemotherapy Agents in the Treatment of Advanced Non-small Cell Lung Cancer: A Meta-Analysis

2008 • 18 citations

Targeted disruption of the HFE gene

1998 • 11 citations

Irinotecan plus carboplatin versus etoposide plus carboplatin in extensive disease small cell lung cancer: Results of the German randomized phase III trial

2009 • 10 citations

Highlights from: the 42nd Annual Meeting of the American Society of Clinical Oncology; Atlanta, GA, June 2006

2006 • 3 citations

Irinotecan plus platinum analog (IP) compared to etoposide plus platinum analog (EP) in extensive stage small cell lung cancer (ED-SCLC): Systematic review with meta-analysis

2009 • 2 citations